« Previous Next » Gastroenterology
Volume 138, Issue 7 , Pages 2207-2210.e1 , June 2010

Spasmolytic Polypeptide-Expressing Metaplasia and Intestinal Metaplasia: Time for Reevaluation of Metaplasias and the Origins of Gastric Cancer

James R. Goldenring
- Nashville VA Medical Center and the Epithelial Biology Center and Departments of Surgery and Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, Tennessee
Ki Taek Nam
- Nashville VA Medical Center and the Epithelial Biology Center and Departments of Surgery and Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, Tennessee
Timothy C. Wang
- Associate Editor and Irving Cancer Research Center, Department of Medicine, Columbia University Medical Center, New York, New York
Jason C. Mills
- Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri
Nicholas A. Wright
- Barts and The London Medical School, Histopathology Unit, Cancer Research UK London Research Institute, London, United Kingdom

References

Correa P. A human model of gastric carcinogenesis. Cancer Res. 1988;48:3554–3560
- MEDLINE
Rokkas T, Filipe MI, Sladen GE. Detection of an increased incidence of early gastric cancer in patients with intestinal metaplasia type III who are closely followed up. Gut. 1991;32:1110–1113
- MEDLINE
- CrossRef
Zivny J, Wang TC, Yantiss R, et al. 2003 Role of therapy or monitoring in preventing progression to gastric cancer. J Clin Gastroenterol. 2003;36:S50–S60
- MEDLINE
- CrossRef
Schmidt PH, Lee JR, Joshi V, et al. Identification of a metaplastic cell lineage associated with human gastric adenocarcinoma. Lab Invest. 1999;79:639–646
- MEDLINE
Lax I, Bellot F, Honegger A, et al. Functional analysis of the ligand binding site of EGF-receptor utilizing chimeric chicken/human receptor molecules. EMBO J. 1989;8:421–427
- MEDLINE